Latest From Qiagen NV
Bio-Techne has reached an agreement to acquire Exosome Diagnostics, putting the firm in a stronger position in the emerging liquid biopsy and precision medicine spaces.
Medtech Insight highlights results from some of the leading IVD players. This week we spotlight Thermo Fisher Scientific, Danaher, Qiagen and Quest Diagnostics. But which among them are this season's earnings winners and losers?
Qiagen has agreed to acquire STAT-Dx, a start-up that developed a multiplex diagnostic for common syndromes, for about $147m in upfront cash, and up to $44m in regulatory and commercial milestones.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Qiagen NV
- Senior Management
Peer M Schatz, CEO
Roland Sackers, CFO
Manuel O Mendez, SVP, Global Commercial Ops.
- Contact Info
Phone: (31) 77 3556600
Venlo, 5912 PL
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.